After Aducanumab: Finding New Treatments For Neurodegenerative Diseases
An Interview With Rising Leader Virginie Buggia-Prevot
Executive Summary
As a freshman interested in neurobiology at Joseph Fourier University in Grenoble, Virginie Buggia-Prevot knocked on the lab door of an esteemed neurosurgeon and professor conducting research on deep brain stimulation. She was hooked; following a PhD in neurobiology and a post doc at the University of Chicago, Buggia-Prevot joined MD Anderson’s Neurodegeneration Consortium, managing strategic alliances and working on drug discovery. In November, she joined Valo as director of neurology discovery, an opportunity to bring new research in neurodegeneration to bear on patients’ lives.
You may also be interested in...
Biogen’s Aducanumab Falls Hard At Panel Review, Leaving US FDA In A Tight Spot
Successful EMERGE trial does not provide substantial evidence of efficacy in Alzheimer’s because it cannot be divorced from its unsuccessful sister study, advisory committee says; panel’s unequivocal rejection leaves agency’s Office of Neuroscience in a tight spot given its strong support for the drug and the help it gave Biogen to get this far.
Khushboo Sharma: Improving Regulatory Science, From Industry To FDA And Back
From pre-med to pharma lab rat to deputy director of operations at the FDA, Khushboo Sharma, a 2021 In Vivo Rising Leader and current VP of science and regulatory affairs at BIO, has spent her career pursuing a goal she says the FDA and biopharma industry have in common: ensuring that innovative drugs get to patients.
Data-Sharing Key To US Supply Chain Resilience And Keeping Drug Costs Under Control
Aside from a few high-profile exceptions, the biopharma industry supply chain has remained secure and resilient during the COVID-19 pandemic, outperforming retail and consumer goods. Chip Davis, Jr., head of the Healthcare Distribution Alliance, spoke with In Vivo about the need for a long-term industrial policy for drug manufacturing, real-time data-sharing and transparency in the supply chain, and minimizing disruptions.